SCHEMBL771940

SCHEMBL771940

CC1CCCN(C(=O)CCC(=O)N2CCC3CCCC=C3C2)C1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
HPGD P15428 3/20 0.50
MEN1 O00255 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
POLB P06746 2/20 0.50
MAPT P10636 1/20 0.50
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.47
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
GAA P10253 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RXFP1 Q9HBX9 1/20 0.40
RECQL P46063 1/20 0.40
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771903 0.95 KMT2A (0.54) KMT2AHPGDMEN1SMN1; SMN2POLB
SCHEMBL770549 0.95 KMT2A (0.54) KMT2AHPGDMEN1SMN1; SMN2POLB
SCHEMBL769880 0.93 ALDH1A1 (0.47) KMT2AHPGDMEN1SMN1; SMN2POLB
SCHEMBL770610 0.89 POLB (0.41) KMT2AHPGDMEN1SMN1; SMN2POLB
SCHEMBL770939 0.88 NPC1 (0.49) KMT2AHPGDMEN1SMN1; SMN2MAPT
SCHEMBL771656 0.87 MAPK1 (0.36) KMT2AHPGDSMN1; SMN2POLBMAPT
SCHEMBL771057 0.86 RECQL (0.42) KMT2AHPGDMEN1SMN1; SMN2POLB
SCHEMBL771900 0.85 ATM (0.39) KMT2AHPGDMEN1SMN1; SMN2ALDH1A1
SCHEMBL770877 0.85 NPC1 (0.43) KMT2AHPGDMEN1SMN1; SMN2POLB
SCHEMBL771285 0.85 KMT2A (0.40) KMT2AHPGDMEN1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 KMT2A 3868/4885HPGD 50/4885MEN1 827/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 KMT2A 3893/4885HPGD 50/4885MEN1 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.